Background: Glioma is one of the most commonly observed tumours, representing about 75% of brain
tumours in the adult population. Generally, glioma treatment includes surgical resection followed by radiotherapy
and chemotherapy. The current chemotherapy for glioma involves the use of temozolomide, doxorubicin, monoclonal
antibodies, etc. however, the clinical outcomes in patients are not satisfactory. Primarily, the blood-brain
barrier hinders these drugs from reaching the target leading to the recurrence of glioma post-surgery. In addition,
these drugs are not target-specific and affect the healthy cells of the body. Therefore, glioma-targeted drug delivery
is essential to reduce the rate of recurrence and treat the condition with more reliable alternatives.
Methods: A literature search was conducted to understand glioma pathophysiology, its current therapeutic approaches
for targeted delivery using databases like Pub Med, Web of Science, Scopus, and Google Scholar, etc.
Results: This review gives an insight to challenges associated with current treatments, factors influencing drug
delivery in glioma, and recent advancements in targeted drug delivery.
Conclusion: The promising results could be seen with nanotechnology-based approaches, like polymeric, lipidbased,
and hybrid nanoparticles in the treatment of glioma. Biotechnological developments, such as carrier peptides
and gene therapy, are future prospects in glioma therapy. Therefore, these targeted delivery systems will be
beneficial in clinical practices for glioma treatment.